Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tyler C. Detomasi has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Substrate Mimicry by Inhibitors of the Mycobacterium tuberculosis 20S Proteasome and Their Activity against Mycobacteria In Vitro and in Macrophages

    by Xilin Gu, Peter J. Rowheder, Zanlin Yu, Alexander Mohapatra, Shichun Lun, Xiuju Jiang, Daqiang Li, Nicholas L. Yan, Tyler C. Detomasi, Daniel F. Torres Pomares, et al.

    The remarkable and problematic capacity of Mycobacterium tuberculosis to persist in the host is dependent on a functional 20S proteasome that is structurally and functionally analogous to its mammalian counterpart. It has been proposed that this enzyme is critical for the bacterium’s adaptive response to a variety of stressors in the host. Here, we report the structure of a rationally designed and species-selective inhibitor of the Mtb 20S proteasome in complex with the enzyme. The inhibitor was inspired by the syringolin natural products—covalent proteasome inhibitors that mimic a substrate. Structure elucidation of the Mtb 20S proteasome-inhibitor adduct via cryo-electron microscopy revealed that the inhibitor mimics a substrate yet engages the active site in a different fashion than the syringolin natural products. Corroboration of this model via the synthesis of hypothetical inhibitors led to the discovery of a more potent inhibitor, as evidenced in kinetic assays for enzyme inhibition. Both inhibitors are permeable to and active in M. tuberculosis. They sensitize the bacterium to chemically and pharmacologically induced nitrosative stress in vitro. Importantly, they suppress the persistence of live mycobacteria in murine and human macrophages.

  • Open Access

    A Prodrug Strategy to Conditionally Trap Therapeutic Payloads for Improved Tumor Retention

    by Deokhee Kang, Apurva Pandey, Garima Kumar, Abijeet Singh Mehta, Tyler C. Detomasi, Dashiell Anderson, Conner Bardine, Garrison Asper, Junyang Qi, Isha Nadig, et al.

    Altered extracellular proteolysis has been exploited to selectively activate therapeutics in diseases such as cancer; however, once activated, extracellular drugs can diffuse away, limiting efficacy. We address this challenge by coupling proteolytic activation with membrane tethering to retain drugs within diseased tissue. To accomplish this, we developed “restricted interaction peptides” (RIPs), a delivery platform that leverages elevated proteolytic activity to activate membrane-interacting peptides, localizing cargos near the site of proteolysis. We demonstrate that RIPs can deliver diverse therapeutic cargos, including cytotoxins and radioisotopes. As proof of concept, we engineered “FRIP,” a RIP designed for cleavage by fibroblast activation protein (FAP), an endoprotease upregulated in solid tumors and fibrosis. Efficient P4–P4’ substrate sequences were identified and incorporated into FRIPs. Cell-based studies showed that, upon activation, the peptide adhered to membranes rapidly internalized and successfully delivered therapeutic cargos. Consistent with this, FRIPs delivering MMAE inhibited proliferation in an FAP-dependent manner. Imaging studies confirmed tumor targeting with minimal uptake in normal tissues. Finally, FRIPs delivering MMAE or Cu-67 exhibited potent antitumor effects. These findings establish membrane tethering as a strategy to enhance drug retention.


  • Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models

    by Luca Lizzadro, Jiapeng Li, Taha Y. Taha, Gilles Degotte, Tyler C. Detomasi, Francisco J. Zapatero-Belinchon, Eric R. Hantz, Sijie Huang, Yusuke Matsui, Will R. Henderson, et al.

    The main proteases (MPro) of coronaviruses are clinically validated targets for antiviral discovery. Herein, we detail the in vivo optimization of uracil-core MPro inhibitors derived from AVI-4516, an in vivo active lead bearing an unactivated propargyl warhead. To expand the anticoronaviral spectrum, we introduced diverse C6 substitution to target the S1' pocket in MPro and observed enhanced cellular activity against various nirmatrelvir-resistant mutants. Pharmacokinetic profiling of 12 analogs revealed overall inferior exposure of the C6 aryl analogs. However, PK profiling across three species identified the improved atropisomeric lead (M)-AVI-4773 (5-(5,6-difluoro-1H-benzo[d][1,2,3]triazol-1-yl)-3-((M)-isoquinolin-4-yl)-6-methyl-1-(prop-2-yn-1-yl)pyrimidine-2,4(1H,3H)-dione), which exhibits rapid-onset oral efficacy in both SARS-CoV-2 and Middle East respiratory syndrome (MERS) mouse models, highlighting a promising chemotype with the potential to deliver anticoronaviral development candidates.


  • Open Access

    Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacy

    by Tyler C. Detomasi, Gilles Degotte, Sijie Huang, Rahul K. Suryawanshi, Amy Diallo, Luca Lizzadro, Francisco J. Zaptero-Belinchón, Taha Y. Taha, Jiapeng Li, Alicia L. Richards, et al.

    The main protease (M Pro ) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a validated drug target. Starting with a lead-like dihydrouracil chemotype identified in a large-library docking campaign, we improved M Pro inhibition >1000-fold by engaging additional M Pro subsites and using a latent electrophile to engage Cys 145 . Advanced leads from this series show pan-coronavirus antiviral activity, low clearance in mice, and for AVI-4773 , a rapid reduction in viral titers >1,000,000 after just three doses. Both compounds are well distributed in mouse tissues, including brain, where concentrations >1000× the 90% effective concentration are observed 8 hours after oral dosing for AVI-4773 . AVI-4516 shows minimal inhibition of major cytochrome P450s and human proteases. AVI-4516 also exhibits synergy with the RNA-dependent RNA polymerase inhibitor, molnupiravir, in cellular infection models. Related analogs strongly inhibit nirmatrelvir-resistant M Pro mutant virus. The properties of this chemotype are differentiated from existing clinical and preclinical M Pro inhibitors and will advance therapeutic development against emerging SARS-CoV-2 variants and other coronaviruses.


  • Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins

    by Aakriti Jain, Isaac Heremans, Gilles Rademaker, Tyler C. Detomasi, Peter Rohweder, Dashiell Anderson, Justin Zhang, Grace A. Hernandez, Suprit Gupta, Teresa von Linde, et al.

    Breakdown of every transmembrane protein trafficked to lysosomes requires proteolysis of their hydrophobic helical transmembrane domains. Combining lysosomal proteomics with functional genomic datasets, we identified lysosomal leucine aminopeptidase (LyLAP; formerly phospholipase B domain–containing 1) as the hydrolase most tightly associated with elevated endocytosis. Untargeted metabolomics and biochemical reconstitution demonstrated that LyLAP is a processive monoaminopeptidase with preference for amino-terminal leucine. This activity was necessary and sufficient for the breakdown of hydrophobic transmembrane domains. LyLAP was up-regulated in pancreatic ductal adenocarcinoma (PDA), which relies on macropinocytosis for nutrient uptake. In PDA cells, LyLAP ablation led to the buildup of undigested hydrophobic peptides, lysosomal membrane damage, and growth inhibition. Thus, LyLAP enables lysosomal degradation of membrane proteins and protects lysosomal integrity in highly endocytic cancer cells.


  • Open Access

    Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-M Pro inhibitors with potent in vivo efficacy

    by Tyler C. Detomasi, Gilles Degotte, Sijie Huang, Rahul K. Suryawanshi, Amy Diallo, Luca Lizzadro, Francisco J. Zaptero-Belinchón, Taha Y. Taha, Jiapeng Li, Alicia Richards, et al.

    The main protease (M Pro ) of SARS-CoV-2 is crucial for viral replication and is the target of nirmatrelvir (the active ingredient of Paxlovid) and ensitrelvir. The identification of new agents with differentiated pharmacokinetic and drug resistance profiles will increase therapeutic options for COVID-19 patients and bolster pandemic preparedness generally. Starting with a lead-like dihydrouracil chemotype from a large-library docking campaign, we improved M Pro inhibition >1,000-fold by engaging additional sub-sites in the M Pro active site, most notably by employing a latent propargyl electrophile to engage the catalytic Cys145. Advanced leads from this series, including AVI-4516 and AVI-4773 show pan-coronavirus antiviral activity in cells, very low clearance in mice, and for AVI-4773 a rapid reduction in viral titers more than a million-fold after just three doses, more rapidly and effectively than the approved drugs, nirmatrelvir and ensitrelvir. Both AVI-4516 and AVI-477 3 are well distributed in mouse tissues, including brain, where concentrations ten or fifteen-thousand times the EC 90 , respectively, are observed eight hours after an oral dose. As exemplar of the series, AVI-4516 shows minimal inhibition of major CYP isoforms and human cysteine and serine proteases, likely due to its latent–electrophilic warhead. AVI-4516 also exhibits synergy in cellular infection models in combination with the RdRp inhibitor molnupiravir, while related analogs strongly inhibit nirmatrelvir-resistant M Pro mutant virus in cells. The in vivo and antiviral properties of this new chemotype are differentiated from existing clinical and pre-clinical M Pro inhibitors, and will advance new therapeutic development against emerging SARS-CoV-2 variants and other coronaviruses. One sentence summary: This manuscript describes the discovery of a new class of potent inhibitors of the SARS-CoV-2 major proteases (M Pro ) with a unique mechanism of inhibition, pan coronaviral activity in cellulo , exquisite selectivity vs. the human proteome, and exceptional in vivo efficacy in SARS-CoV-2 infection models that surpasses that of currently approved agents.

  • Open Access

    Proteases influence colony aggregation behavior in Vibrio cholerae

    by Tyler C. Detomasi, Allison E. Batka, Julie S. Valastyan, Molly A. Hydorn, Charles S. Craik, Bonnie L. Bassler, Michael A. Marletta


  • Open Access

    A Prototype Assay Multiplexing SARS-CoV-2 3CL-Protease and Angiotensin-Converting Enzyme 2 for Saliva-Based Diagnostics in COVID-19

    by Vallabh Suresh, Daniel A. Sheik, Tyler C. Detomasi, Tianqi Zhao, Theresa Zepeda, Shyam Saladi, Ummadisetti Chinna Rajesh, Kaleb Byers, Charles S. Craik, Vincent Jo Davisson

    With the current state of COVID-19 changing from a pandemic to being more endemic, the priorities of diagnostics will likely vary from rapid detection to stratification for the treatment of the most vulnerable patients. Such patient stratification can be facilitated using multiple markers, including SARS-CoV-2-specific viral enzymes, like the 3CL protease, and viral-life-cycle-associated host proteins, such as ACE2. To enable future explorations, we have developed a fluorescent and Raman spectroscopic SARS-CoV-2 3CL protease assay that can be run sequentially with a fluorescent ACE2 activity measurement within the same sample. Our prototype assay functions well in saliva, enabling non-invasive sampling. ACE2 and 3CL protease activity can be run with minimal sample volumes in 30 min. To test the prototype, a small initial cohort of eight clinical samples was used to check if the assay could differentiate COVID-19-positive and -negative samples. Though these small clinical cohort samples did not reach statistical significance, results trended as expected. The high sensitivity of the assay also allowed the detection of a low-activity 3CL protease mutant.


  • Open Access

    Characterization of a unique polysaccharide monooxygenase from the plant pathogen Magnaporthe oryzae

    by Alejandra Martinez-D’alto, Xia Yan, Tyler C. Detomasi, Richard I. Sayler, William C. Thomas, Nicholas J. Talbot, Michael A. Marletta

    Blast disease in cereal plants is caused by the fungus Magnaporthe oryzae and accounts for a significant loss in food crops. At the outset of infection, expression of a putative polysaccharide monooxygenase ( Mo PMO9A) is increased. Mo PMO9A contains a catalytic domain predicted to act on cellulose and a carbohydrate-binding domain that binds chitin. A sequence similarity network of the Mo PMO9A family AA9 showed that 220 of the 223 sequences in the Mo PMO9A-containing cluster of sequences have a conserved unannotated region with no assigned function. Expression and purification of the full length and two Mo PMO9A truncations, one containing the catalytic domain and the domain of unknown function (DUF) and one with only the catalytic domain, were carried out. In contrast to other AA9 polysaccharide monooxygenases (PMOs), Mo PMO9A is not active on cellulose but showed activity on cereal-derived m ixed (1→3, 1→4)- β -D- g lucans (MBG). Moreover, the DUF is required for activity. Mo PMO9A exhibits activity consistent with C4 oxidation of the polysaccharide and can utilize either oxygen or hydrogen peroxide as a cosubstrate. It contains a predicted 3-dimensional fold characteristic of other PMOs. The DUF is predicted to form a coiled-coil with six absolutely conserved cysteines acting as a zipper between the two α-helices. Mo PMO9A substrate specificity and domain architecture are different from previously characterized AA9 PMOs. The results, including a gene ontology analysis, support a role for Mo PMO9A in MBG degradation during plant infection. Consistent with this analysis, deletion of Mo PMO9A results in reduced pathogenicity.


  • Open Access

    A moonlighting function of a chitin polysaccharide monooxygenase, CWR-1, in Neurospora crassa allorecognition

    by Tyler C Detomasi, Adriana M Rico-Ramírez, Richard I Sayler, A Pedro Gonçalves, Michael A Marletta, N Louise Glass

    Organisms require the ability to differentiate themselves from organisms of different or even the same species. Allorecognition processes in filamentous fungi are essential to ensure identity of an interconnected syncytial colony to protect it from exploitation and disease. Neurospora crassa has three cell fusion checkpoints controlling formation of an interconnected mycelial network. The locus that controls the second checkpoint, which allows for cell wall dissolution and subsequent fusion between cells/hyphae, cwr (cell wall remodeling), encodes two linked genes, cwr-1 and cwr-2. Previously, it was shown that cwr-1 and cwr-2 show severe linkage disequilibrium with six different haplogroups present in N. crassa populations. Isolates from an identical cwr haplogroup show robust fusion, while somatic cell fusion between isolates of different haplogroups is significantly blocked in cell wall dissolution. The cwr-1 gene encodes a putative polysaccharide monooxygenase (PMO). Herein we confirm that CWR-1 is a C1-oxidizing chitin PMO. We show that the catalytic (PMO) domain of CWR-1 was sufficient for checkpoint function and cell fusion blockage; however, through analysis of active-site, histidine-brace mutants, the catalytic activity of CWR-1 was ruled out as a major factor for allorecognition. Swapping a portion of the PMO domain (V86 to T130) did not switch cwr haplogroup specificity, but rather cells containing this chimera exhibited a novel haplogroup specificity. Allorecognition to mediate cell fusion blockage is likely occurring through a protein–protein interaction between CWR-1 with CWR-2. These data highlight a moonlighting role in allorecognition of the CWR-1 PMO domain.